In September, officials touted leucovorin as a potential treatment for thousands of children with autism. Now the FDA is walking back from that claim as the drug is approved for a rare genetic condition, not autism. CNN's Meg Tirrell reports.Read more: https://t.co/gy0nYX7dGy https://t.co/a5yhaiW6Ek ...

Core Viewpoint - The FDA has approved leucovorin for treating cerebral folate transport deficiency, a neurological disorder, which the Trump administration previously promoted as a potential therapy for autism [1] Group 1 - The approval of leucovorin marks a significant development in the treatment of cerebral folate transport deficiency [1] - The drug has been associated with potential benefits for autism, although its primary approval is for a different neurological condition [1]

The Food and Drug Administration approved leucovorin, a drug the Trump administration has touted as a potential therapy for autism, to treat cerebral folate transport deficiency, a neurological disorder with some symptoms similar to autism. https://t.co/UdQpJBSyou ...

FDA declines to endorse leucovorin for autism after Trump administration touted the drug as a potential treatment. https://t.co/LoGTc6ehOC ...

Core Insights - The U.S. FDA approved leucovorin for treating cerebral folate deficiency, an ultra-rare genetic disorder, but not for broader autism treatment due to insufficient data [1][2][3] - The approval marks a significant shift from previous promises made by government officials regarding the drug's potential for autism treatment [1][2] Drug Approval Details - Leucovorin, a form of folate, is now approved for cerebral folate deficiency based on a systematic review of existing literature rather than clinical trial data [1][2] - The FDA noted that conducting randomized controlled trials was not feasible due to the rarity of the disorder, with only 20 to 50 case studies available [1][2] Market Implications - GSK's Wellcovorin, the branded version of leucovorin, will allow all generic versions to include the new indication, potentially increasing production of the drug [1][2] - The FDA has encouraged drug manufacturers to ramp up production in light of the new approval [1][2] Evidence and Research - Limited evidence exists for leucovorin's efficacy in treating autism, with small studies suggesting a link between autoantibodies and folate deficiency in some children with autism [1][2] - The American Academy of Pediatrics does not recommend routine use of leucovorin for autism due to a lack of substantial evidence [1][2]

Core Insights - Tylenol use among pregnant women decreased significantly after President Trump's comments linking the medication to autism, with a 10% overall drop in prescriptions [1] - The most notable decline was a 16% reduction in prescriptions for pregnant women aged 15-44, peaking at a 20% drop in the third week following the announcement [1] - The study highlighted that thousands of women may have gone without necessary pain or fever treatment due to fear stemming from the President's statements [1] Company Impact - Kenvue Inc., the owner of the Tylenol brand, may face challenges due to the negative perception created by the association with autism, impacting sales and public trust [1] - The study indicated that despite the initial drop, prescriptions for Tylenol began to recover after several weeks, suggesting potential resilience in the brand's reputation [1] Industry Trends - The analysis revealed a concurrent increase in prescriptions for leucovorin, a treatment for children with autism, which rose by 71% during the same period, indicating a shift in treatment preferences among healthcare providers [1] - The findings underscore the broader implications of public health messaging and its influence on medication usage patterns, particularly in sensitive demographics like pregnant women [1]

Core Insights - Oncolytics Biotech Inc. has initiated a Phase 2 study for pelareorep in metastatic colorectal cancer, aiming to confirm previous efficacy data with preliminary results expected by the end of 2026 [1][2] Study Design and Objectives - The trial will involve second-line RAS-mutated, microsatellite-stable mCRC patients, randomized to either a control arm (bevacizumab and FOLFIRI) or an experimental arm (pelareorep, bevacizumab, and FOLFIRI) [2] - Each arm is expected to enroll 30 patients who have failed initial platinum-based chemotherapy, with the primary endpoint being objective response rate (ORR) [2] - Secondary endpoints include progression-free survival (PFS), overall survival (OS), safety, and biomarker analysis [2] Previous Study Results - The prior REO 022 study showed promising results with a median OS of 27 months and median PFS of 16.6 months for pelareorep, significantly better than the standard-of-care median OS of 11.2 months and PFS of 5.7 months [3] - The ORR for pelareorep-containing therapy was 33%, compared to approximately 10% for standard treatment [3] Regulatory Designation - Pelareorep in combination with bevacizumab and FOLFIRI has received Fast Track Designation from the U.S. FDA for second-line KRAS-mutant, MSS mCRC [3][6] Clinical Implications - The potential to improve clinical outcomes in the second-line setting could significantly benefit patients globally affected by colorectal cancer [4] - An effective immunotherapy could enhance treatment options, especially as younger patients are increasingly diagnosed with colorectal cancer [4] Company Overview - Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an investigational immunotherapeutic agent designed to activate immune responses against cancer [5] - The company is also pursuing strategic partnerships to accelerate development and maximize commercial impact [6]

Core Insights - Pfizer Inc. announced positive topline progression-free survival results from Cohort 3 of the pivotal BREAKWATER trial, which evaluated BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and FOLFIRI in patients with previously untreated metastatic colorectal cancer with a BRAF V600E mutation [1] Group 1 - The BRAFTOVI regimen demonstrated statistically significant results in the trial [1]

Core Insights - Pfizer Inc. announced positive results from Cohort 3 of the BREAKWATER trial, which evaluates the efficacy of BRAFTOVI® (encorafenib) in combination with cetuximab and FOLFIRI in patients with untreated metastatic colorectal cancer (mCRC) with a BRAF V600E mutation [1] Group 1 - The BREAKWATER trial is pivotal for assessing the BRAFTOVI combination regimen [1] - The study focuses on patients with previously untreated metastatic colorectal cancer [1] - The combination includes BRAFTOVI, cetuximab (marketed as ERBITUX®), and FOLFIRI (fluorouracil, leucovorin, and irinotecan) [1]

After President Trump talked up leucovorin as a possible treatment for autism, demand for the FRAT blood test spiked https://t.co/KWixEVgvEV ...